Publisher of Iranian Journals and Conference Proceedings

Please waite ..
CIVILICAWe Respect the Science
Publisher of Iranian Journals and Conference Proceedings
عنوان
Paper

Novel Approaches Using Immune Checkpoint Inhibitors in Treatment of Glioblastoma Multiforme (GBM)

تعداد صفحات: 2 | تعداد نمایش خلاصه: 109 | نظرات: 0
سال انتشار: 1397
کد COI Paper: IPMCMED03_089
زبان Paper: Englishglish
نسخه کامل Paper در کنفرانس ارائه نشده است و در دسترس نیست.

مشخصات نویسندگان Paper Novel Approaches Using Immune Checkpoint Inhibitors in Treatment of Glioblastoma Multiforme (GBM)

Mohammad Amin Dehghani - Student Research Committee of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Seyyed Hossein Hassanpour Ezzati - Young Researchers and Elite Club, Yasooj Branch, Islamic Azad University, Yasooj, Iran
Fatemeh Dehghani - Department of Genetics, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Golnoosh Alikarami - School of Medicine, Hamedan University of Medical Sciences, Hamedan, Iran

چکیده Paper:

Introduction: Glioblastoma multiforme (GBM) is recognized as an aggressive primary brain tumor. In general, GBM activates different immune escape mechanisms and has been identified as an immunosuppressive neoplasm. Lately, durable tumor remissions in numerous types of cancer and high response rates in terms of clinically-relevant enhancements have been associated with the application of immune checkpoint inhibitors) anti-PD-1 and anti- CTLA-4).Methods: In this study, we searched the PubMed database to find English articles related to our topic applying the keywords of GBM, immune checkpoint inhibitors, CTLA-4 inhibitor, PD-1 inhibitor and therapeutic strategies.Results: Checkpoint regulators have been recognized as a favorable GBM treatment since the use of checkpoint inhibitors in cancer immunotherapy. Researchers performed the first extensive phase three trials in 2014 to evaluate the safety and efficiency of nivolumab in GBM patients, followed by another large phase III trial of nivolumab in patients diagnosed with GBM. The integration of radiation and checkpoint inhibitors has been assessed in various clinical studies. Moreover, researchers are currently examining the concomitant use of checkpoint inhibitors and common treatments, such as corticosteroids, radiotherapy, temozolomide, and bevacizumab by conducting relevant clinical trials. Mortality rate of patients with brain metastases can reduced in case of simultaneous application of radiotherapy and ipilimumab. The importance of assessing the role of immune checkpoint inhibitors in GBM is justified by considering the success rate of immunotherapy in other cancers and our recent comprehension of the link between the immune system and the brain. Conclusion: It is recommended that GEMM of GBMs be used by researchers in future studies to improve the effectiveness of immunotherapy on GBM and assess the mechanisms of immune responses made against tumors so that optimized, novel, and appropriate checkpoint blockade treatments could be designed for this deadly cancer.

کلیدواژه ها:

GBM, immune checkpoint inhibitors, CTLA-4 inhibitor, PD-1 inhibitor, therapeutic strategies

کد Paper/لینک ثابت به این Paper

برای لینک دهی به این Paper می توانید از لینک زیر استفاده نمایید. این لینک همیشه ثابت است و به عنوان سند ثبت Paper در مرجع سیویلیکا مورد استفاده قرار میگیرد:

https://civilica.com/doc/858230/

کد COI Paper: IPMCMED03_089

نحوه استناد به Paper:

در صورتی که می خواهید در اثر پژوهشی خود به این Paper ارجاع دهید، به سادگی می توانید از عبارت زیر در بخش منابع و مراجع استفاده نمایید:
undefined, undefined و undefined, undefined و undefined, undefined و undefined, undefined,1397,Novel Approaches Using Immune Checkpoint Inhibitors in Treatment of Glioblastoma Multiforme (GBM),سومین کنگره بین المللی پزشکی شخصی ایران,Tehran,,,https://civilica.com/doc/858230

در داخل متن نیز هر جا که به عبارت و یا دستاوردی از این Paper اشاره شود پس از ذکر مطلب، در داخل پارانتز، مشخصات زیر نوشته می شود.
برای بار اول: (1397, Dehghani, Mohammad Amin؛ Seyyed Hossein Hassanpour Ezzati و Fatemeh Dehghani و Golnoosh Alikarami)
برای بار دوم به بعد: (1397, Dehghani؛ Hassanpour Ezzati و Dehghani و Alikarami)
برای آشنایی کامل با نحوه مرجع نویسی لطفا بخش راهنمای سیویلیکا (مرجع دهی) را ملاحظه نمایید.

Research Info Management

Certificate | Report Paper

Export Citation info of this Paper to research management softwares

علم سنجی و رتبه بندی Paper

مشخصات مرکز تولید کننده این Paper به صورت زیر است:
نوع مرکز: medical university
تعداد مقالات: 2,463
در بخش علم سنجی پایگاه سیویلیکا می توانید رتبه بندی علمی مراکز دانشگاهی و پژوهشی کشور را بر اساس آمار مقالات نمایه شده مشاهده نمایید.

New RelatedPapers

Share this paper

WHAT IS COI?

COI is a national code dedicated to all Iranian Conference and Journal Papers. the COI of each paper can be verified online.

Support